Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CNSX:ATTNYSEARCA:BRWNYSE:TAM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATTAbattis BioceuticalsC$0.00C$0.05▼C$0.74N/AN/A1.42 million shsN/ABRWSaba Capital Income & Opportunities Fund$7.87+0.4%$7.53$6.86▼$8.04N/AN/A170,147 shs31,576 shsTAM(TAM)$0.00$18.95▼$26.96N/AN/A330,661 shsN/A7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATTAbattis Bioceuticals0.00%0.00%0.00%0.00%0.00%BRWSaba Capital Income & Opportunities Fund0.00%-1.01%+3.16%+1.95%+10.58%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATTAbattis BioceuticalsN/AN/AN/AN/AN/AN/AN/AN/ABRWSaba Capital Income & Opportunities FundN/AN/AN/AN/AN/AN/AN/AN/ATAM(TAM)N/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATTAbattis Bioceuticals 0.00N/AN/AN/ABRWSaba Capital Income & Opportunities Fund 0.00N/AN/AN/ATAM(TAM) 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATTAbattis BioceuticalsN/AN/AN/AN/AN/AN/ABRWSaba Capital Income & Opportunities FundN/AN/AN/AN/AN/AN/ATAM(TAM)N/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATTAbattis BioceuticalsN/AN/A0.00N/AN/AN/AN/AN/AN/ABRWSaba Capital Income & Opportunities FundN/AN/A0.00∞N/AN/AN/AN/AN/ATAM(TAM)N/AN/A0.00N/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATTAbattis BioceuticalsN/AN/AN/AN/AN/ABRWSaba Capital Income & Opportunities FundN/AN/AN/AN/AN/ATAM(TAM)N/AN/AN/AN/AN/ALatest TAM, WTAN, ATT, and BRW DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date6/3/2025BRWSaba Capital Income & Opportunities Fundmonthly$0.085013.3%6/10/20256/10/20256/30/20255/2/2025BRWSaba Capital Income & Opportunities Fundmonthly$0.085013.5%5/9/20255/9/20255/30/20254/2/2025BRWSaba Capital Income & Opportunities Fundmonthly$0.085013.1%4/9/20254/9/20254/30/2025(Data available from 1/1/2013 forward)Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATTAbattis BioceuticalsN/ABRWSaba Capital Income & Opportunities FundN/ATAM(TAM)N/AInsider OwnershipCompanyInsider OwnershipATTAbattis BioceuticalsN/ABRWSaba Capital Income & Opportunities FundN/ATAM(TAM)N/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATTAbattis BioceuticalsN/AN/AN/ANot OptionableBRWSaba Capital Income & Opportunities FundN/AN/AN/ANot OptionableTAM(TAM)N/AN/AN/ANot OptionableTAM, WTAN, ATT, and BRW HeadlinesRecent News About These CompaniesHow old was Sally Ride when she died? Cause of death explored as new doc tells story of America’s first female astronautJune 16 at 7:24 AM | soapcentral.comWho was Sally Ride’s husband? All about Steven Hawley as partner Tam O’Shaughnessy discusses life-long relationship with astronautJune 16 at 7:24 AM | soapcentral.com‘Sally’ explains why a trailblazing astronaut chose to stay in the closetJune 16 at 7:24 AM | msn.comMarin schools chief: ‘Reconsider’ Tam High consultant contracts decisionJune 15 at 4:21 PM | msn.comCanada’s top doctor Dr. Theresa Tam steps down amid alarming health crisesJune 14 at 12:16 PM | msn.comCanada's top doctor Theresa Tam leaving position when term ends June 20June 13 at 9:13 PM | msn.comNew documentary ‘Sally’ tells the full life story of America’s first female astronautJune 13 at 9:13 PM | msn.comCanada’s top doctor Theresa Tam to leave role June 20June 13 at 4:12 PM | globalnews.caCP NewsAlert: Chief Public Health Officer Dr. Theresa Tam leaving position on June 20June 13 at 4:12 PM | thestar.comCanada's top doctor Theresa Tam leaving positionJune 13 at 4:12 PM | nationalpost.comTheresa Tam bids farewell as Canada’s top public health officerJune 13 at 4:12 PM | theglobeandmail.comCanada's top doctor Theresa Tam leaving role at end of term June 20June 13 at 4:12 PM | cbc.caTamala Edwards announces move to Action News at 10amJune 13 at 6:08 AM | 6abc.comMarin schools chief: 'Reconsider' Tam High consultant contracts decisionJune 13 at 6:08 AM | msn.comTam teachers rally to restore consultants for Black student supportJune 12, 2025 | marinij.comMarin IJ Readers’ Forum for June 11, 2025June 11, 2025 | marinij.comVan-Tam praises impact of football abuse schemeJune 11, 2025 | bbc.co.ukCouncil shake-up follows close vote on sewer rate increaseJune 11, 2025 | msn.comHRS: Sailor of the YearJune 10, 2025 | wavy.comA First Kiss from America’s First Woman in SpaceJune 10, 2025 | newyorker.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in Value3 High-Paying Dividend Stocks That Still Have Safe PayoutsBy Chris Markoch | May 27, 2025View 3 High-Paying Dividend Stocks That Still Have Safe PayoutsThese 3 Stocks Could Be Back in Play Before You Know ItBy Gabriel Osorio-Mazilli | June 10, 2025View These 3 Stocks Could Be Back in Play Before You Know ItNextracker’s Solar Surge: Will It Shatter Its All-Time High?By Thomas Hughes | May 18, 2025View Nextracker’s Solar Surge: Will It Shatter Its All-Time High?Hormel Stock Near Lows, But Tariff Relief Could Boost OutlookBy Chris Markoch | May 29, 2025View Hormel Stock Near Lows, But Tariff Relief Could Boost OutlookTAM, WTAN, ATT, and BRW Company DescriptionsAbattis Bioceuticals CNSX:ATTAbattis Bioceuticals Corp. is a specialty biotechnology company. The Company aggregates, incubates, integrates and invests in the natural health product and botanical drug development industry. It operates through the segment of producing, licensing and marketing ingredients and formulas for use in the biopharma, nutraceutical, cosmetic and animal nutrition markets. The Company, through its subsidiaries, develops and commercializes natural health (nutraceutical) products, and conducts research and development to create plant-based (botanical) intellectual property and ingredients for the pharmaceutical and bioceutical markets, among others. It offers products and services, such as botanical blends and formulas; cannabidiol ingredients; functional foods and beverages, and analytical services. It is focused on creating botanical formulations, medical marijuana and specialized health products for pain caused by inflammation, and mental ailments.Saba Capital Income & Opportunities Fund NYSEARCA:BRW$7.87 +0.03 (+0.38%) As of 12:01 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Saba Capital Income & Opportunities Fund is a closed-ended fixed income mutual fund launched by Voya Investment Management LLC. The fund is managed by Saba Capital Management, L.P. It invests in the fixed income markets of the United States. The fund seeks to invest in securities of companies operating across diversified sectors. It primarily invests in floating rate secured senior loans, with an emphasis on top-tier, non-investment grade senior loans. The fund seeks to invest in loans with maturities of one to ten years. It benchmarks the performance of its portfolio against the S&P/LSTA Leveraged Loan Index. The fund was formerly known as Voya Prime Rate Trust. Saba Capital Income & Opportunities Fund was formed on December 2, 1987 and is domiciled in the United States.(TAM) NYSE:TAMTaminco Corp is a producer of alkylamines and alkylamine derivatives. The Company's products are used by its customers in the manufacturing of everyday products primarily for the agriculture, water treatment, personal and home care, animal nutrition and oil and gas end-markets. It operates in 19 countries with seven production facilities and, as of December 31, 2012, had an installed production capacity of 1,272 thousand tons. The Company has three business segments: Functional Amines, Specialty Amines, and Crop Protection. In March 2014, the Company announced that it completed the acquisition of the formic acid business of Kemira Oyj. Its main shareholder is Eastman Chemical Company. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 2 Reasons Adobe Stock Is Ready to Rally This Year AMD Accelerates Stack Development: Share Price to Follow Alphabet Enters a Bull Market: Is It Time to Buy? Micron Joins Latest $200 Billion United States Investment Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones RH Stock Rockets on Surprise Profit and Tariff Shift Tariff Talks Advance, What Taiwan Semiconductor Can Deliver Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
